Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.

Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Fate ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...

French pharma major Sanofi’s saw its shares edge up 1% by early afternoon, despite announcing a disappointment for a vaccine ...

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its ...

Filing of the 2024 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report ...